Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Safety and Tolerability of NT-0796, Nadroparin, and Lidocaine Hydrochloride in Healthy Volunteers and Patients with Parkinson’s Disease

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial examines people with Parkinson's Disease, a brain condition that leads to shaking, stiffness and slowed movements, and evaluates the oral capsule called NT-0796. During the study, occasional use of lidocaine hydrochloride – an injection that temporarily numbs the area – and nadroparin calcium – an injection that helps prevent blood clots – may be required for certain procedures. The purpose of the research is to determine whether NT-0796 is safe and well tolerated.

Participants will take the study medication and attend a few scheduled visits where simple blood draws and other routine tests are performed to assess the drug’s pharmacokinetics (how the body absorbs and clears the medication) and pharmacodynamics (how the medication affects the body). Researchers will record any side effects, known as adverse events, and any changes in standard blood test results. The overall study period is short, with regular monitoring to ensure participant safety.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and screening

    After signing the informed consent form, you will undergo screening procedures that include a review of your medical history, a physical examination, and laboratory tests to confirm eligibility for the study.

  2. Step 2

    Baseline visit

    On the first study day, baseline measurements such as vital signs, neurological assessment for parkinson's disease, and additional laboratory samples will be collected before any medication is given.

  3. Step 3

    Administration of study drug nt-0796

    You will receive one oral capsule of nt-0796 containing 300 mg. the capsule is taken by mouth as instructed by the study staff.

  4. Step 4

    Administration of background medications

    As part of the study protocol, you may receive an injection of lidocaine hydrochloride solution (10 mg per ml) and an injection of nadroparin calcium (1 IU). these injections are given according to the schedule defined by the investigators.

  5. Step 5

    Monitoring and safety assessments

    Throughout the study period, you will attend regular visits where vital signs, neurological status, and any side effects will be recorded.

    Repeated laboratory tests will be performed to monitor safety and to detect any changes in clinical values.

  6. Step 6

    Final assessment and study completion

    At the end of the study, a final set of evaluations similar to the baseline visit will be performed.

    Study medication will be discontinued, and you will receive a summary of the study results that relate to safety and tolerability.

Who can join the trial?

5 criteria

  • Sign the informed consent form and be willing to follow the study’s instructions.
  • Be between 18 and 75 years old at the time of screening.
  • Agree to have spinal fluid taken through a lumbar puncture (a short needle placed in the lower back to collect fluid).
  • If you are a woman who could become pregnant (women of child‑bearing potential), you must either avoid sex or use a very reliable form of contraception, and you cannot donate eggs, from 28 days before the first dose until 90 days after the last dose.
  • If you are a man, you must use a condom (called barrier protection) when having sex with a woman who could become pregnant during the study and for 90 days after the last dose, and you should ask your partner to use an effective birth‑control method if she could become pregnant, is pregnant, or is nursing.

Who cannot join the trial?

4 criteria

  • Pregnant or breastfeeding women cannot join the study; this means anyone who knows they are pregnant, has a positive pregnancy test, or is feeding a baby with breast milk.
  • Problems with the immune system exclude a person; this includes diseases that weaken the body's defenses such as autoimmune diseases (where the body attacks itself), HIV (a virus that damages immune cells), asplenia (missing or non‑functioning spleen), repeated serious infections, or taking medicines that suppress the immune system for more than 14 days in the past 6 months (or any single use in the past 30 days).
  • Severe drug allergies prevent participation; this covers any confirmed allergic reaction to medications, including skin rashes or anaphylaxis (a rapid, life‑threatening allergic reaction), as well as other significant allergies.
  • Psychiatric or cognitive issues that could interfere with the study or following instructions also exclude a person; examples are mental health conditions or problems with thinking, memory, or understanding that might affect participation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • NT-0796

    is an experimental oral capsule being studied for the first time in people who are healthy and in patients with Parkinson’s disease. The trial is looking at how safe it is, how well people can tolerate it, and how the drug moves through the body and affects the disease. Participants take the capsule by mouth during the study.

  • Lidocaine

    is a medication given by injection that numbs a small area of the body. In this trial it is used to provide local anesthesia during any minor procedures or blood draws, making the process more comfortable for the participants.

  • Nadroparin

    is an injection that works as an anticoagulant, which means it helps prevent blood clots. It is given to participants as a precaution to reduce the risk of clotting while they are part of the study.

What is already known about the treatment

  • NT-0796

    This medication is taken by mouth as a 300 mg capsule. It is an experimental drug that is still being studied and has not yet been approved for general medical use. The main purpose of the trial is to see if it can help people with Parkinson’s disease by influencing brain chemicals that control movement. It is classified as an investigational neuro‑protective agent that works at the molecular level to modulate dopamine‑related pathways.

  • Lidocaine Hydrochloride

    This medication is given as an injection of a 10 mg/ml solution. It is an established drug that is widely used and listed in medical literature as a local anesthetic. It is mainly used to numb tissue for minor surgeries or procedures by blocking sodium channels in nerve cells, which stops pain signals. It belongs to the class of local anesthetics.

  • Nadroparin Calcium

    This medication is administered by injection, typically in a small volume measured in international units. It is a well‑known anticoagulant that is approved and described in many medical references. Its primary use is to prevent blood clots, especially after surgery, by enhancing the activity of antithrombin, which then inhibits clotting factors in the blood. It is classified as a low‑molecular‑weight heparin.

Investigated diseases

Parkinson's disease - Parkinson's disease is a brain disorder that slowly damages nerve cells that control movement. It usually begins with a slight tremor in one hand, stiffness, or slower movements. Over time the tremor can appear on both sides of the body and walking may become difficult. Muscle stiffness may increase, making everyday tasks harder. Non‑motor changes such as sleep problems, mood changes, or reduced sense of smell can also develop as the condition advances.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-503203-29-00Protocol codeNT-0796-P002Estimated enrolment14 patientsSponsorNodthera Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.